Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Presbyopia

• Status: Recruiting
• Trial end date: 2023-06-29
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of AGN-241622 ophthalmic solution for the first time in human participants

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan

Criteria

Inclusion Criteria:

• Age 40 to 65 at the time of study participation.

• Be a nonsmoker and nonuser of nicotine-containing products within the previous 1 year.

• Be able and willing to follow study instructions and complete all required study visits in the opinion of the study doctor.

Exclusion Criteria:

• History of alcohol or substance abuse within the 5 years prior to study participation.

• Enrollment in another investigational drug or device study within 30 days of study participation.

• Women who are pregnant, nursing, or planning a pregnancy during the study.